US FDA Declines to Authorize Fluvoxamine for Covid-19 Treatment


But the drug regulator, in a document, stated: “Based on the review of available scientific evidence, the FDA has determined that the data is insufficient to conclude that fluvoxamine may be effective in the treatment of non-hospitalized patients with Covid-19 to prevent progression to severe disease and/or hospitalization.”

“Therefore, FDA has determined that the criteria for issuance of an EUA are not met and is declining to issue an EUA covering fluvoxamine for the treatment of Covid-19 at this time,” it added.

Currently,

fluvoxamine is FDA-approved for the treatment of obsessions and compulsions in patients with obsessive compulsive disorder (OCD) in children 8-17 years of age and adults.

Fluvoxamine for Covid-19 Treatment

But in December, 2021, Dr. David R Boulware, a professor at University of Minnesota in the US, submitted a request to the FDA to grant emergency use authorization (EUA) to fluvoxamine for the outpatient treatment of Covid positive persons above 24 years of age to prevent progression to severe disease and/or hospitalization.

The agency said it reviewed available information derived from several clinical trials investigating the use of fluvoxamine for the treatment of Covid-19.

It noted that “the treatment benefit of fluvoxamine was not persuasive when focusing on clinically meaningful outcomes”, meaning no reduction in hospitalizations and deaths.

Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI), currently used to treat mental health conditions such as depression and obsessive-compulsive disorders.

It has been used since the 1990s for various conditions and its safety profile is well-known.

Source: IANS

Source link

Home Remedies

%d bloggers like this: